Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial - CNBC

AI Summary1 min read

TL;DR

Novo Nordisk's stock dropped 10% after its next-generation weight loss drug failed to outperform Eli Lilly's rival in a clinical trial, leading to negative market reactions.

Tags

Novo Nordiskweight loss drugEli Lillyclinical trialstock decline
  1. Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial  CNBC
  2. Novo Nordisk's obesity drug falls short against Eli Lilly's in trial  Reuters
  3. Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival  Bloomberg
  4. Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial  The Wall Street Journal
  5. Novo Nordisk’s next-gen obesity drug stumbles in comparison study  statnews.com

Visit Website